Loading…
Lifecore Biomedical, Inc. is projected to rise to $6.54 by 2027, a +36% move from its current price of $4.82. LFCR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.68 | $4.82 | $4.97 | +0.07% |
| May 30 | $4.63 | $4.83 | $5.03 | +0.14% |
| May 31 | $4.59 | $4.83 | $5.08 | +0.21% |
| Jun 1 | $4.56 | $4.83 | $5.13 | +0.28% |
| Jun 2 | $4.53 | $4.84 | $5.17 | +0.36% |
| Jun 3 | $4.50 | $4.84 | $5.20 | +0.43% |
| Jun 4 | $4.48 | $4.84 | $5.24 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.48 | $4.84 | $5.24 | +0.50% |
| Week 2 | $4.36 | $4.87 | $5.43 | +1.00% |
| Week 3 | $4.28 | $4.89 | $5.60 | +1.50% |
| Week 4 | $4.21 | $4.92 | $5.74 | +2.01% |
| Week 5 | $4.15 | $4.94 | $5.88 | +2.52% |
| Week 6 | $4.11 | $4.97 | $6.01 | +3.03% |
| Week 7 | $4.06 | $4.99 | $6.13 | +3.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies.
The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LFCR is a Healthcare stock that currently trades at $4.93 per share and has a market capitalization of $184.92M, ranking 3888.
The current price aligns with the forecast’s 2026 average of $4.93, and the long-term outlook shows a bullish trajectory with notable upside into the 2030s and beyond. The year-by-year forecast outlines a path from near-term stability to substantial gains over time.
From 2027 onward, averages rise from $6.99 (2027) to higher levels, with 2030 at $9.00 on average and substantial upside by 2040 ($22.57) and 2050 ($40.81). The outlook includes bullish sentiment for most years, with larger upside potential reflected in higher max values in later years (e.g., 2034 max $24.51, 2050 max $79.00).
In the near term, the forecast portrays continued upside potential across the longer horizon, though 2026 is labeled neutral and the first year of attention is 2027 with growing optimism.
A major floor 24.1% below — a decisive break under it would weaken the trend.
The nearest floor, 9.1% below — buyers have tended to step in here.
The nearest ceiling, 11.6% above — a clean break opens room to run.
A major ceiling 83.0% above — clearing it would confirm fresh momentum.
Key LFCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LFCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.82 | Sell | $4.78 | Buy |
| MA 10 | $4.63 | Buy | $4.74 | Buy |
| MA 20 | $4.77 | Buy | $4.76 | Buy |
| MA 50 | $4.62 | Buy | $5.07 | Sell |
| MA 100 | $6.08 | Sell | $5.69 | Sell |
| MA 200 | $6.76 | Sell | $6.27 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.52 | Neutral |
| Stoch RSI (14) | 75.68 | Neutral |
| CCI (20) | 13.52 | Neutral |
| Williams %R (14) | -26.67 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 0.63 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 73.33 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 62.60 | Neutral |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.99 | Sell |
| ADX (14) | 15.52 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bullish at present. RSI14 is 50, with a 50-day simple moving average of $4.64 and a 200-day simple moving average of $6.78.
Key near-term levels are a support of $4.38 and a resistance of $5.38, with a 30-day range from $4.03 to $6.03.
Annualized volatility sits at 60%, signaling meaningful price fluctuations within the month and contributing to the risk profile in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.66 | $4.82 | $7.10 | 0% | Neutral | |
| $5.15 | $6.54 | $8.83 | +36% | Bullish | |
| $5.81 | $7.59 | $10.64 | +58% | Bullish | |
| $6.26 | $8.39 | $12.11 | +74% | Bullish | |
| $6.04 | $8.27 | $12.25 | +72% | Bullish | |
| $6.26 | $8.75 | $13.25 | +82% | Bullish | |
| $6.43 | $9.15 | $14.14 | +90% | Bullish | |
| $7.18 | $10.41 | $16.36 | +116% | Bullish | |
| $9.08 | $13.38 | $21.39 | +178% | Bullish | |
| $9.03 | $13.54 | $21.97 | +181% | Bullish | |
| $11.94 | $19.26 | $33.35 | +300% | Bullish | |
| $19.11 | $35.03 | $66.62 | +627% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.66 | $4.82 | $5.65 | +0.00% |
| June 2026 | $4.13 | $4.86 | $5.86 | +0.83% |
| July 2026 | $4.33 | $5.14 | $6.29 | +5.81% |
| August 2026 | $4.38 | $5.24 | $6.48 | +1.93% |
| September 2026 | $4.36 | $5.24 | $6.54 | -0.01% |
| October 2026 | $4.53 | $5.48 | $6.89 | +4.50% |
| November 2026 | $4.67 | $5.68 | $7.19 | +3.67% |
| December 2026 | $4.56 | $5.56 | $7.10 | -2.00% |
Click any year to see its month-by-month LFCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LFCR could reach as high as $7.10, with a base case around $4.82 and support toward $3.66 — roughly 0% from $4.82. Price action looks broadly range-bound.
Expect LFCR to range from $5.15 to $8.83 through 2027. The $6.54 average target implies a +36% move from current prices. That is up +36% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LFCR price prediction for 2028 points to an average of $7.59 (low $5.81, high $10.64) — a potential gain of +58% on today's $4.82. Momentum favours further upside here.
In 2029, LFCR is projected to trade between $6.26 and $12.11, averaging $8.39 — a potential gain of +74% from today's $4.82. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Lifecore Biomedical, Inc.'s 2030 outlook centres on $8.27, within a $6.04 to $12.25 range. That is -1% versus the projected 2029 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2031, LFCR could reach as high as $13.25, with a base case around $8.75 and support toward $6.26 — roughly +82% from $4.82. Buyers look set to stay in control over this stretch.
Expect LFCR to range from $6.43 to $14.14 through 2032. The $9.15 average target implies a +90% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The LFCR price prediction for 2033 points to an average of $10.41 (low $7.18, high $16.36) — a potential gain of +116% on today's $4.82. Buyers look set to stay in control over this stretch.
In 2034, LFCR is projected to trade between $9.08 and $21.39, averaging $13.38 — a potential gain of +178% from today's $4.82. That is up +29% on the projected 2033 average. Momentum favours further upside here.
Lifecore Biomedical, Inc.'s 2035 outlook centres on $13.54, within a $9.03 to $21.97 range. That is up +1% on the projected 2034 average. That marks a +181% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LFCR could reach as high as $33.35, with a base case around $19.26 and support toward $11.94 — roughly +300% from $4.82. Momentum favours further upside here.
Expect LFCR to range from $19.11 to $66.62 through 2050. The $35.03 average target implies a +627% move from current prices. That is up +82% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LFCR today (≈ 207.46888 LFCR) could be worth
$7,268.2
+$6,268.2 (+627%) by 2050 · US Dollar
Based on the average projected LFCR price of $35.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LFCRwould be worth at today's price.
$1,000 invested in LFCR on May 27, 2025 (≈ 142.857143 LFCR) would be worth
$688.57
-$311.43 (-31.1%) today · 0.69× · US Dollar
Based on a LFCR entry price of $7 vs. today's $4.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.57 | $1,054.7 | +5.5% |
| 1 month ago | $5.08 | $948.82 | -5.1% |
| 3 months ago | $7.37 | $654 | -34.6% |
| 6 months ago | $7.9 | $610.13 | -39.0% |
| 1 year ago | $7 | $688.57 | -31.1% |
| All time (5.0y) ago | $11.64 | $414.09 | -58.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LFCR forecast.
Our base-case forecast reaches $9.60 around 2033.
Implied market cap at $9.60: $360.09M
Looking at the multi-year forecast, 2026 shows a min of $3.66, a 2026 average of $4.93, and a max of $7.40 with a neutral sentiment. The years that follow are projected to be bullish, with 2027 averaging $6.99 (ROI 41.8%), 2028 averaging $8.11 (ROI 64.6%), 2029 averaging $9.01 (ROI 82.7%), and 2030 averaging $9.00 (ROI 82.5%).
The trajectory continues higher: 2031 avg $9.53 (ROI 93.2%), 2032 avg $10.09 (ROI 104.6%), 2033 avg $11.81 (ROI 139.6%), 2034 avg $15.14 (ROI 207.1%), and 2035 avg $15.23 (ROI 208.8%). By 2040, the average is projected at $22.57 (ROI 357.8%), and by 2050 the average reaches $40.81 (ROI 727.9%), all with bullish sentiment.
These figures are estimates and not guarantees; they reflect model projections for LFCR’s price path and involve substantial uncertainty and risk.
Tap a question to reveal the answer.
The forecast lists year 2030 avg $9.00, min $6.51, max $13.46, ROI 82.5%, sentiment BULLISH.
The forecast shows bullish sentiment for 2027 through 2050 with rising averages (e.g., 2027 avg $6.99, 2030 avg $9.00, 2040 avg $22.57, 2050 avg $40.81); 2026 is neutral. These are estimates, not guarantees.
No. The 2035 forecast shows max $25.04 and avg $15.23, so $50 is not projected for 2035 within the given data; by 2050 the max is $79.00.
Near term, the forecast indicates a neutral stance in 2026 with min $3.66, avg $4.93, max $7.40. The 30-day range is $4.03–$6.03 and the stock shows 60% annualized volatility, signaling notable price fluctuations.
Current price is $4.93 and market cap is $184.92M.
Lifecore Biomedical, Inc. Community Discussion
0Share your Lifecore Biomedical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.